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INTRODUCTION 
 One of the major characteristics of burns is the formation of an 
eschar, which is made up burned and traumatized tissue. The presence of 
the eschar that covers the entire injured area prevents accurate diagnosis 
of the burns depth and may lead to the extension of injury to neighboring, 
originally undamaged tissues. The eschar also serves as a medium for 
bacterial growth, and is therefore a source of infection, contamination and 
sepsis. As a result, prompt removal of the eschar is imperative to the 
healing of burns1-5. 
 The current method of choice for burn debridement is surgical 
tangential excision as advocated by Janzekovic in 1970. While effective, 
surgical debridement has several major disadvantages. Tangential 
excision is non-selective and may sacrifice healthy surrounding tissues, 
often converting a partial thickness burn into a full thickness defect1,6-8. 
Furthermore, surgical excision is painful and exposes patients to the risks 
of repeated anesthesia and significant bleeding. Enzymatic debridement 
has been suggested in the past, however the agents used have had several 
drawbacks. In particular, most enzymatic agents require prolonged and 
repeated exposures in order to achieve sufficient debridement often 
necessitating further surgical or chemical debridement. Furthermore, 
repeated application, especially when using moist occlusive dressings for 
extensive periods of time, may result in local infection and promote 
systemic spread of the infectious process9-13. 
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 The ideal debridement agent or method should have the following 
attributes: 
1. Safety i.e., without any systemic and local adverse effects.  
2. Selectivity: resulting in removal of the necrotic eschar 
without affecting the surrounding viable tissue, thus 
permitting accurate diagnosis of the extent of the original 
damage. 
3. Effective : removing the entire eschar, preferably in a single 
application. 
4. Rapid: resulting in rapid reduction of the infection risk and 
permitting sequential debridement of large areas over a short 
time span. 
5. Simple to use and cost effective. 
Bromelain is a well-known group of enzymes extracted from 
pineapple fruits or stems. It contains more than 50 different components 
and is widely used as an over-the-counter food additive and is also used 
in the cosmetic industry. The late, Drs.Klein and Houck,14-15 attempted to 
debride burn eschars with bromelain. They initially used commercially 
available lyophilized preparations achieving good but inconsistent 
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results16-18. Further work led to the development of a proprietary 
extraction method that purified active ingredients from the crude 
bromealin to obtain a highly effective debriding mixture that they called 
“Eschalyse”19. The developers claimed that the effective action of 
Eschalyse was due to the synergistic activity of its various components. 
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AIM OF THE STUDY 
 The aim of the current study was to evaluate the efficacy of burn 
wound debridement using the Eschalyse enzyme preparation as well as to 
evaluate its  
1. Safety : ie without any systemic and local adverse effects. 
2. Slectivity : resulting in removal of the necrotic eschar 
without affecting the surrounding viable tissue. 
3. Effectiveness : remove the entire eschar preferably in a 
single application. 
4. Rapidity : resulting in rapid reduction of the infection risk  
and permitting sequential  debridement of large areas over a 
short time   span. 
5. Simple to use and cost effective. 
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REVIEW OF LITERATURE 
 Improvements in burn care originated in specialized units 
specifically dedicated to the care of burned patients. The interactive 
multidisciplinary team has proven to be the least expensive and most 
efficient method of treating major burn injury, of which the initial acute 
care is only a small part of the total treatment. Burn patients often 
requires years of supervised rehabilitation, reconstruction, and 
psychosocial support. Omission of any step in the treatment regimen by 
any of the burn team members, including the burn surgeon, nurses, 
therapists, nutritionists, or psychosocial support staff, can result in less 
than optimal outcomes. 
EPIDEMIOLOGY 
 A study conducted in United States says that approximately 1.1 
million individual annually are burned seriously enough to seen health 
care; about 45,000 die. More than 90% of burns are preventable; nearly 
one half are smoking related or due to substance abuse.23,24  
 The burn size associated with a 50% mortality rate has increased 
from 30% of the total body surface area (TBSA) to greater than 80% 
TBSA in otherwise healthy young adults.25,26 The quality of burn care is 
no longer measured only by survival, but also by long-term function and 
appearance. Although small burns are not usually life threatening, they 
need the same attention as larger burns to achieve optimal outcomes. 
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 As with other forms of trauma, burns frequently affect children and 
young adults. In children under 8 years of age, the most common burns 
are scalds, usually from the spilling of hot liquids.27 In older children and 
adults, the most common burns are flame-related, usually the result of 
house fires, the ill-advised use of flammable liquids as accelerants, or 
smoking – or alcohol – related.28 Chemicals or hot liquids, followed by 
electricity, and then molten or hot metals most often cause work-related 
burns.29 
NORMAL SKIN FUNCTION 
 The skin is the largest single organ of the body. It conforms to 
body contours, flexes with muscular action and is sufficiently elastic to 
allow for drastic changes in body contours. Through a variety of sensors, 
the skin provides a perception of the environment, body positions, heat, 
texture and pressure, even in the absence of the other senses. The bi-layer 
composition of the skin provides an external water repellent and internal 
vapor barrier and is the anchor tissue for all dermal appendages. This 
elastic organ protects internal structures from injury and is an effective 
barrier to the instruction of dirt, dust and microorganisms. Through the 
controlled excretion of water and solutes, body heat is dissipated, and in 
concert with the hypothalamus, provides the human organism the means 
to maintain a stable core temperature in a variety of external 
environments. Additionally sunlight stimulates the skin to produce 
Vitamin D, which is an essential nutrient for normal absorption and 
utilization of calcium and phosphorus. 
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 Scattered throughout the dermis are three types of connective cells; 
mast cells which secrete histamine and heparin, phagocytic histiocytes 
and the reparative fibroblast. Burn injury stimulates each of these cells 
producing a series of local and systemic changes. 
BURN DEPTH 
 The depth of burn varies depending on the degree of tissue  
damage. Burn depth is classified into degree of injury in the epidermis, 
dermis, subcutaneous fat, and underlying structures. 
Depths 
First  Degree Injury localized to the epidermis 
Superficial second degree Injury to the epidermis and 
superficial dermis 
Deep second degree Injury through the epidermis and 
deep into the dermis 
This degree Full-thickness injury through the 
epidermis and dermis into the 
subcutaneous fat 
Fourth degree Injury through the skin and 
subcutaneous fat into underlying 
muscle or bone 
 
BURN SIZE 
 
 Determination of burn size estimates the extent of injury.  Burn 
size is generally  assessed by the “rule of nines”. In adults, each upper 
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extremity and the head and neck are 9% of the TBSA. The lower 
extremities and the anterior and posterior trunk are 18%  each, and the 
perineum and genitalia are assumed  to be  1% of the TBSA. Children 
have a relatively larger portion of the body surface area in the head and 
neck, which is compensated for by a relatively smaller surface area in the 
lower extremities. Infants have 21% of the TBSA in the head and neck 
and 13% in each leg, which incrementally approaches the adult properties 
with increasing age. 
MECHANISM OF INJURY 
Thermal Burns 
 Heat denatures cellular proteins resulting in a cell coagulation 
necrosis. The severity of the injury is related to the intensity of the heat, 
i.e., temperature, the length of exposure, and the conduction capacity of 
the skin at the site of the injury.31-34  
 Burns caused by hot liquids are usually partial thickness unless 
prolonged contact with the causative agent occurs although the relative 
thinness of the skin of the elderly and young children may result in 
deeper injuries than initially suspected. Full thickness injuries are most 
frequently the result of direct flames, boiling water or grease, molten 
metals, synthetic material, and other substances, likely to adherent to the 
skin, such as tar or asphalt. Immediate cooling of these adherent 
substances will reduce the amount of tissue damage resulting from such 
exposure. 
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Chemical injuries 
 The extent and severity of a chemical injury is dependent upon the 
agent’s strength or concentration, quantity, physical state, duration of 
contact and penetrating power. Injuries caused by chemical exposure 
differ from thermal injuries in the rate at which tissue destruction occurs 
and the length of time necrosis continues. Tissue necrosis will continue to 
occur as long as the undiluted agent remains on the skin or until the 
caustic agent is chemically expended. 
 The scientific evidence of the exact mechanism of chemical injury 
is ill-defined and dependent upon the specific chemical agent. In general, 
agents can be classed into five groups, based on the manner in which they 
coagulate proteins. These are: (1) oxidizing agents, such as sodium 
hypochlorite, (2) corrosives, such as phenol and lye, (3) salt forming 
agents such as formic, tannic and hydrochloric acids, (4) dessicants such 
as sulfuric acid and (5) vessicants such as DMSO and nitrogen mustard. 
In addition to cutaneous injury, some agents cause systemic toxicity with 
symptoms such as hypocalcemia, hepatic necorsis and renal tubular 
damage. 
 Alkalis penetrate deeply, causing liquefaction necrosis and fat 
saponification. Rumack reported temperatures of 96°C in cat esophagi 
after lye ingestion, contributing heat damage to the chemical injury. 
Acids, in contrast, are potent dessicants and cause tissue injury by cellular 
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dehydration and lysis in addition to local heat generation. Acids do not 
penetrate as well as alkalis due to the protective eschar formation from 
the heat  generated protein coagulation. 
Electrical injuries 
 Electrical burns produce a visible cutaneous injury which belies the 
actual damage sustained. The extent of injury is dictated by the type of 
current (direct vs indirect), the current voltage and amperage, resistance 
of the body parts through which current passes and the duration of 
contact. Most high voltage current tends to take a direct path from the 
point of contact to ground whereas lower voltage alternating current more 
frequent results in cardiac arrest and death. A 15 mill ampere or greater 
and death. A 15 mill ampere or greater current will produce tetanic 
muscle contractions making it impossible release the contact until heat 
generation results tissue carbonization. 
 Electricity flows along the path of least resistance, which in the 
body is along the nerves and blood vessels. Different tissues offer 
different resistances, ranging from least to greatest they are nerve, blood, 
muscle, skin, tendon, fat and bone. The more resistant the tissue, the 
greater the heat produced as electiricty passes through it. Perspiration or 
moisture reduce skin surface resistance by 12-25 fold38 however, as the 
skin is the usual point of contact, entry and exit wounds occur at the point 
of electrical contact and the site of grounding. 
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 True electrical injuries are produced when electricity passes 
through the body after contact with a conductor. The characteristic entry 
and exit wounds represent deep issue destruction. The body part(s) 
through which the electricity passed may appear viable but muscle tissue 
death is progressive and may not be accurately assessed until 4 – 5 days 
following injury. The arc burn is caused by current coursing external to 
the body, jumping from the contact point to the ground and is most 
frequently associated with high tension sources. Characteristically, these 
injuries have scattered sports of injury due to the high temperature of the 
arc. Flame injuries may also result from electrical contact when the 
electricity sparks or arcs to clothing igniting them. 
Radiation injury 
 Ionizing radiation i.e., the type produced by X-rays, radioisotopes 
and classic radioactive substances, causes injury to the body through its 
ability to penetrate cells and deposits energy within them. When 
sufficiently intense, ionizing radiation kills cells through inhibiting 
mitosis. The sensitivity of cells to radiation damage varies considerable 
with the different stages of cell life. In addition to cutaneous injury, 
excessive exposure to radiation can produce life-threatening systemic 
effects such as extensive hemorrhage, aplastic anemia and destruction of 
lymphatic tissue. These injuries characteristically result in full thickness 
dermal injury and due to the extensive cellular damage, are slow to heat. 
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Pathophysiology of the burn wound 
 Three concentric zones of burn injury have been described. The 
central zone of coagulation represents the direct heat damage, consisting 
of protein coagulation with complete cessation of blood flow through 
arterial and venous channels, which results in irreversible tissue death. 
Additionally, if a large body surface area is severely damaged, the 
reduction of circulating volume results in tissue hypoxia, with a 
concomitant shift to anaerobic metabolism and lactic acid accumulation, 
causing further structural damage. If this zone extends below the dermal 
appendages, a full thickness injury results whereas if lies above the 
dermal appendages, a partial for spontaneous health. The zone of 
coagulation is surrounded by the zone of stasis, characterized by oxygen 
and nutrient starved tissue. If the area of stasis is protected from infection 
and dessication, the area may ultimately survive and heal. The zone of 
hyperemia surrounds the other areas and is the site of minimal cell 
involvement early spontaneous recovery, if provided with appropriate 
cases. 
 Severe burn injury produces venous stasis, microthrombi formation 
and vascular endothelial sloughing. As the blood’s viscosisty changes, 
white cells marginate and red cell rouleaux formation occurs, creating a 
physical barrier between the phagocytes and any bacteria present. 
Additionally, this barrier compromises oxygen, antibody and phagocyte 
delivery to the burned tissue interface. 
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 Using light staining techniques electron microscopy and various 
histochemical stains, deCamara et al41 obtained  structural as well as  
cellular information  on the nature of thermal injury. After producing an 
epidermal scald burn in guinea pigs, they observed coagulative necrosis 
of epidermal cells with epidermal – dermal separation within 2 hours. 
Loss of basement membrane continuity and dermal edema, with 
disruption of superficial dermal capillaries, was noted at eight hours post 
injury. A complete inflammatory response was present at 96 hours, with 
dermal infiltration by polymorphonuclear leukocytes. With the 
documentation of the progressive nature of the burn would and the 
realization that the height of local damages does not occur immediately 
after the burn, the potential exists for reversing or preventing the burn 
wound progression. 
Inflammatory Response 
 The capillaries and venules in the burn wound become highly 
permeable to fluid, electrolytes and proteins in the area of burn wound. 
Netsky and Leiter in 1943 documented the passage of horse serum 
protein across the capillary endothelium of the dog following thermal 
injury and the results were confirmed with radioactive dyes and Evans 
blue.42,43 Massiha and Manafo44 demonstrated that venous circulation was 
more compromised than arterial  in the zone of stasis. Polymorphonuclear 
leukocytes (PMN)adhere  to the vessel walls and platelet aggregation 
occurs, increasing venous resistance and causing post burn edema.45 In 
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server thermal injury, micorthrombi form and occlude the 
microcirculation, incurring further cell death. Chemical mediators 
released from the site of injury are responsible for the development of the 
typical inflammatory response. 
 The inflammatory response to thermal injury results in rapid and 
dramatic edema formation. This transcapillary transport has been 
extensively studied by Arturson and colleagues46 who attribute the 
phenomena to the combined effects of three mechanisms: (1) dilation of 
resistance vessels resulting in increased transcapillary filtration pressure, 
(2) increased extravascular osmotic activity in damaged tissue and 
(3)increased microvascular permeability to macromolecules. The 
combined effects of these alterations result in rapid loss of vascular fluid 
into the interstitium. A large amount of literature exists on morphological 
ultra structure changes following thermal injuries which could account 
for the fluid shift. Many authors have suggested the open endothelial 
intercellular junctions allow fluid and protein to escape47,48 and it appears 
that the junctional openings occurs in venules first. 
 Heat denatured proteins stimulate the acute inflammatory process 
by activating the complement cascade. The activated complement system 
facilitates liberation of various permeability factors at the site. Histamine 
is one of the first mediators released and elevated levels of histamine 
have been measured in lymph drainage following thermal injury.49 Other 
investigation  have documented high levels of prostaglandins in wound 
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secretions and blister fluid, principally PGE-1, PGE-2 and PGF-2a.50,51,51 
Recently the endoperoxides and thromboxanes, which cause platelet 
aggregation and contract vascular and airway smooth muscle have been 
found and quantitated in burn blister fluid.52 
 Polymorphonuclear neutrophil leukocytes stick to the wall in large 
numbers within minutes of thermal injury and their oxidative metabolism 
suddenly increases during phagocytic activity.53,54 NADPH oxidases 
present in the cell wall reduce oxygen to superoxide radical and hydrogen 
peroxide, which kill the bacteria or destroy the phagocytised material. 
Cell damage is prevented by the presence of superoxide dismutase (SOD) 
and catalyse in the cytosol. In the burned tissued, the overwhelming 
phagocytic response results in relative deficiencies of SOD and catalyse 
and excess free radicals damage the cell walls, releasing arachonidonic 
acid and stimulating the formation of prostaglandins, endoperoxides, 
prostacyclin, thromboxane, A2 and B2, resulting in cell contraction and 
macromolecular leakage. A significant reduction in post burn edema has 
been observed following delivery of SOD and activate catalyse in 
experimental rat models.55 
Water and heat loss 
 The burn wound exudates and evaporate continuously from the 
burn wound surface creating a hyperosmotic zone which attracts more 
water from the underlying vital tissues, establishing a vicious cycle. 
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Every square meter of burn surface area results in the loss of 3750 mls of 
water and each liter of water requires 580 kcal of energy to evaporate.56 
This excessive loss of heat from the body is further enhanced by 
decreased insulation afforded by damaged skin, increasing radiation heat 
loss. A massive catabolic response, with the release of catecholamines, 
glucagon and relative insulin inefficiency results in proteolysis, lipolysis, 
gluconeogensis and increased substrate flow to liver.57-61 These changes 
are clinically observed as decreased body weight, excessive nitrogen loss 
or body wasting and increased oxygen consumption. This hyper 
metabolic response can be modified to a certain extent by increasing the 
ambient temperature62 and the proper nutritional support.63 
Alteration in host response and sensistivity to infection 
 Several factors are responsible for the decreased resistance to 
infection in the burn wound. These include: 
1. Epidermal loss exposes vital tissues to bacterial colonization 
and invasion. 
2. The burn eschar and exudates are an ideal media for growth 
of bacteria 
3. Coagulative necrosis and loss of circulation prevents 
humoral defences from reaching the affected tissue and 
4. Alterations in humoral antibody activity. 
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Macromolecular leakage into the burned areas, catabolism and 
reduced immunoglobulin synthesis result in a decreased concentration of 
all individual immunoglobulin levels, reducing direct and indirect 
neutralization activity or triggering of the complement cascade. Specific 
cell mediated immunity is down regulated as seen by altered T4/T8 ratio 
with an increase in suppressor cells and natural killer cells (NK cells) 
number  and function decreases. Further research to study the alteration in 
cell mediated is necessary to understand their function. 
Non specific cellular immune response 
 After the burn, the consumption of complement reduction serum 
immunoglobulin concentrations and multiple defects in 
polymorphonuclear leukocyte functions appear. They are: (1) decreased 
chemotaxis (2) random migration, (3) reduced phagocytosis rates and (4) 
impaired bactericidal capacity. Consumption of stimulatory factors47 and 
or appearance of inhibitors following burns injury is considered 
responsible for reduced chemotaxis and the occurrence of random 
migration. Defects in killing ability of gram positive organisms by 
polymorphonuclear leukocytes have been documented by many 
authors64,65 so it is that reduced ability to phagocytize the particles. The 
reticuloendothelial system as well as bone marrow granulopoiesis,66 are 
depressed in burn patient, reducing factors influencing the opsonization 
of foreign microorganisms. 
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Eschar separation and wound healing 
 As the acute, non-specific inflammatory response reaches its peak 
two or three days following thermal injury, the small, still functional 
vessels regain their integrity and reabsorb the extravased fluid. 
Marcrophages appear in the area and the invading colonized bacteria 
secrete collagenase and other proteases, starting the separation (lysis) of 
dead from live tissue. The more  infected the wound, the quicker eschar 
separation occurs. In deeper burns, wound macrophages play a major role 
in wound healing by relasing multiple factors.67 Angiogenesis factor 
(molecular weight 2000 – 20,000) is secreted by hypoxic 
macrophages68,69 marginated at the wound edges, start neovascularization 
and granulation tissue formation. Deeper macrophages with adequate 
oxygenation, secrete growth factors which stimulate fibroblast 
proliferation, deposition of collagen, fibronectin and 
glycosaminoglycan.70,71 Excessive bacterial prolifeation retards healing 
through release of excessive proteases. If the wound has not healed within 
14 days, myofibroblast-sfibroblast bundles form and deposit excess 
collagen while mast cells release mucopolysaccarhides and histamine 
creating the basis for hypertrophic sear formation. 
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BROMELAIN 
The pineapple plant, ananas comosus, has long been used for 
medicinal purposes. Native cultures used it as a digestive aid and as a 
remedy for skin disorders.72 A compound called bromelain, which was 
found to be highly concentrated in mature pineapple stems73 has since 
been linked to the medicinal properties. Research on bromelain has been 
conducted for decades in Europe and Asia, and in recent years it has been 
of interest in the United States. Although most of the available 
information comes from in vitro and animal studies or anecdotal 
evidence, rather than randomized, controlled clinical trials, bromelain has 
been shown  to exhibit beneficial therapeutic effects while maintaining 
low toxicity and producing few harmful or undesired side effects. In 
particular, bromelain is reported to have anti-inflammatory, 
antiedematous, anticoagulant, and antimetastatic properties, and has also 
been shown to enhance antibiotic activity.72,74,75 
WHAT IS BROMELAIN 
 Bromelain is crude, aqueous extract derived from pineapple stems 
and fruits. It is composed primarily of sulfhydrayl proteolytic exzymes 
that have protein –digesting and milk-clotting properties. Although  there 
has been some controversy over the years as to whether the  enzymes 
found in the stem and fruit are distinguishable as separate enzymes, 
current literature indicates that there are four distinct proteases in 
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pineapples the two major enzymes are now described as stem bromelain 
and fruit bromelain. Several additional components have been found in 
bromelain, including peroxidase, acid phosphatase, several protease 
inhibitors, and organically bound calcium,76 but their activities not well 
understood. Some studies indicate that proteolytic enzymes are not solely 
responsible for bromelain’s pharmacological effects. Thus, further 
research is needed to determine whether the other components contribute 
to bromelain’s medicinal properties. 
COMMERCIAL  AVAILABILITY AND RECOMMENDED USE 
 Bromelain is categorized as a food additive by the U.S.Food and 
Drug Administration and is on the list of substances generally recognized 
as safe.77 The commercially available product is most often made from 
stem bromelain, whereby the extract is removed from cooled pineapple 
juice through centrifugation, ultrafiltration, and lyophilization and the 
remaining substance is made available to the public in the form of a 
powder, cream, tablet, or capsule. It is available in pure form or in 
multienzyme combinations (Debridase, Phlogenzym, and Traumanase). 
 Bromelain appears to be most effective when taken orally. In vitro 
studies have shown that low doses of bromelain are readily degraded by 
protease inhibitors in blood plasma and that oral administration may  help 
bromelain retain its proteolytic activity.78 Theoretically bromelain could 
also be degraded in the digestive tract; however the glycostylated nature 
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of bromelain contributes to its functional stability79 and may also prevent 
proteolytic degradation in the intestine. It has been suggested that 
bromelain be taken on an empty stomach, as it can interest with certain 
types of food.80 
 Recommended dosages of bromelain are available only through the 
scientific literature and vary depending on clinical indication. Most 
studies suggest 500 to 1500 mg/day taken in divided doses. Bromelain’s 
activity is measured in gelatin digesting units, milk-clotting units. 
Federation  Internationale  Pharmaceutiques units. or Rorer units, and 
many manufacturers sell bromelain products that are standardized to 2000 
gelatindigesting units in  500 mg tables.80 
THERAPEUTIC BENEFITS AND MECHANISMS OF ACTION 
Bromelain may be of particular interest in plastic surgery because 
of its apparent antiedematous, anti-inflammatory, and anticoagulation 
proprieties. Additional evidence suggets that bromelain may be beneficial 
in pain reduction, wound healing, burn debridement, and 
ischemia/reperfusion. It may even be an effective adjuvant to antibiotic 
therapy. The various mechanisms involved  in these processes are just 
beginning to be understood. 
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Pain 
 Bromelain may be effective at reducing  pain. In early studies, 
patients who were treated with bromelain experienced statistically 
significant decreases in pain associated with mediolaterial episiotomy81 
and in pain response to bradykinin that was topically applied to open 
blisters.82 In a more recent study of mild acute knee pain in healthy 
adults, bromelain was shown to have a dose –dependent effect on the 
reduction of physical symptoms and improvement of general well 
being.83 However bromelain was not effective and was no better than 
standard treatment. Placebo, or control in reducing pain associated with 
delayed onset muscle Soreness.84 
Edems  
 Several studies have shown bromelain’s antiedematous properties. 
In a double blind, place bo controlled study, bromelain was shown to 
reduce edema and ecchymoses in patients who experienced surgical (e.g. 
rhinoplasty)  or nonsurigcal trauma to the face. The  investigator 
suggested that the resolution of edema and ecchymoses in the  bromelain 
treated subjects required one third to one half fewer days than would have 
been expected if these same patients has received placebo instead of 
active treatment.85 In a study of ischemia/reperfusion injury in rabbits. 
Neumayer et al. observed reduced interstitial edema in rabbits treated 
with  Phlogenzym (MUCOS Pharma GmbH & Co., Gerestried, Germany) 
a combination of bromelain. trypsin, and rutin, compared with rabbits that 
were not treated.86 
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Inflammation 
 There is evidence that bromelain acts as an anti-inflammatory 
agents. In a rat model of knee joint acute inflammation,inflammatory 
exudates from bromelain treated rats had reduced concentrations of the 
immung response.87 Another mechanism of action relates to bromelain’s 
ability to alter leukocyte expression of cell surface molecules. Hale et al. 
found that bromelain removes several types of cell surface molecules. 
thereby decresing leukocyte adhesion and activation ultimately resulting 
in decreased inflammation.78 
 Recent studies suggest that bromelain may be beneficial in treating 
inflammatory diseases. In a mouse model of inflammatory bowel disease, 
bromelain was found to decrease the clinical and histological severity of 
spontaneous colitis and colonic inflammation. While the  proteolytic 
activity of bromelain seemed to be related to the reduction in 
inflammatory bowel disease symptoms., the exact mechanisms of action 
have yet to be determined.88 Secor et al found that systemic bromelain 
treatment reduced the inflammatory process in a mouse and model of 
allergic airway disease.89 In addition anecdotal evidence suggests that 
bromelain may be effective in treating mild ulcerative colitis. A 67 year –
old woman and a 60 year  old woman, both with ulcerative colitis, 
reported improved conditions  after self-treatment with bromelain. In both 
cases, improvement of disease was confirmed by endoscopic 
examination. 
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Would Healing 
 Boirmelain may have beneficial in soft tissue wound healing. In a 
double blind, controlled clinical trial investigating the effects of 
bromelain on episiotomy wounds. Howat and lewis reported faster rates 
of reduction of edema and bruising in subjects who received bromelain 
treatment compared with subjects who received placebo.90 The authors 
noted,  however, that none of the results reached statistical significance.  
In a study of wound healing in healthy adults, an oral nutritional 
supplement containing bromelain, other protease the soft tissue would 
healing time when administered during the early phase of wound healing. 
However, it is important to note that the efficacy of each component of 
the supplements was not determined, and it is unknown if the components 
had an additive or synergistic effect. 
Platelet Aggregation 
 Several earlier studies have suggested that bromelain may be an 
effective anticoagulant. In vitro and in vivo studies93,94 have shown 
bromelain to reduce adenosine 5 diphosphate induced platelet aggregation 
by degrading fibrinogen. Bromelain was more effective at degrading  
purified fibrinogen rather than fibrinogen in plasma,94 possibly because of 
the action of protease inhibitors in the plasma. In a more recent study, 
Glaser and Hiberg report that bromelain decreased adenosine 5 
diphosphate – and thrombin receptor – activated peptide – 6 induced 
platelet aggregatioin, most likely by altering fibrinogen receptors and 
blocking the formation of frbrin. 
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Antibiotics  
 Bromelain has been shown to enhance the action of antibiotics. In 
an early study, bromelain was found to increase tissue permeability to 
antibiotics, although the results were not statistically significant. Tinozzi 
and Venegoni found a statistically significant95 increase in serum and 
tissue levels of amoxicillin in subjects treated with the antibiotic and 
bromelain.96 More recently, bromelain was shown to be effective at 
enhancing the activity of antibiotics inchildren with sepsis. Shahid et al., 
observed a statistically significant decrease in the number of days it took 
for fever to subside and for the withdrawal of hemodynamic support in 
the children who received phlogenzym with antibiotics compared with 
the children who received antibiotic therapy alone.97 
Burn Debridement  
 Bromelain may be an effective alternative to surgical escharotomy 
in patients with deep burns. Results of in vitro and in vivo studies show 
that bromelain preparations can effectively debride full-thickness burns in 
pig skin in less than 24 hours.. The preparations affected only burned skin 
and resulted to minimal blood loss.98 Debridase (Biotechnology General 
L.TD. Kiryat, Malchi, Israel). a bromelain-derived preaparation, has also 
been shown to be an effective burn-debriding agent. In a preliminary 
study of 130 patients with deep second  and third degree burns, 
Rosenberg et al. found that, in most cases treatment with Debridase 
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resulted in complete debridement of eschar after only one or two brief 
applications; however, the investigation note that data were incomplete 
for a large number of patients, and the non comparative nature of the 
study did not allow for a comparison between debridase and standard of 
care.99 In a procine model of burn induced compartment syndrome, 
circumferential limb burns treated with Debridase exhibited a statistically 
significant reduction in intra compartmental pressures compared with 
untreated burns and enzymatic digestion of burn eschar effectively 
cleaned the wound area without damaging viable tissue.100 
Ischemia/Reperfusion 
 Neumayer et al., found that Phlogenzym had a protective effect on 
skeletal muscle during ischemia/reperfusion studies in rabbits. The 
authors suggest that bromelain’s ability to reduce platelet and leukocyte 
aggregation may have reduced clotting in the microvessels, thereby 
preventing the no-reflow phenomenon.86 
Toxicity and Side Effects 
 Bromelain has been shown to have low toxicity. In several animal 
studies, the median lethal dose during oral administration was greater 
than 10g/kg. When bromelain was administered intravenously and 
intraperitioneally, the median lethal dose ranged from 20 to 35 mg /kg 
and from 36 to 85.2 mg/kg respectively. 
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 Most studies of bromelain report a low incidence of adverse 
effects. In a review of clinical studies that investigated bromelain’s effect 
on osteoarthritis, no serious adverse events were reported however, there 
were some cases of gastro intestinal problems, headache, tiredness, dry 
mouth, skin rash, and unspecified allergic reactions. In these studies, 
bromelain was administered at dosages ranging from 540 to 1890 
mg/day. Higher dosages of bromelain tended to have higher incidences of 
adverse drug reactions compared with standard treatment.101 
 Other investigators have reported isolated cases of allergic reaction 
and exacerbation of asthma symptoms as a result of occupational 
exposure to bromelain. In most cases, adverse reactions occurred after 
inhalation of bromelain: however some patients experienced 
gastrointestinal discomfort after per oral challenge with pineapple. The 
respiratory and gastrointestinal symptoms in these cases were found to be 
the result of immunoglobulin-E mediated reactions to bromelain. 
 Some authors have suggested that bromelain’s anticogulant 
properties could increase bleeding when it is taken in combination with 
other medications, such as aspirin and warifarin.105 
 Despite the few reports adverse events, bromelain is generally 
considered to be safe, but it  is important to note that most of human 
studies involving bromelain included adult subjects. Thus there is little 
information on the safety of bromelain for children younger than  18 
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years of age. In addition, little information is available on the safety of 
bromelain when it is administered at higher doses, when it is taken in 
combination with other medications, or when it is taken long term. 
FUTURE RESEARCH 
Although bromelain has been studied for decades in Europe and 
Asia and more recently in the United States, most of the available 
literature desecribes  results of in vitro or animal studies. Very few 
randomized, controlled clinical trials have been conduced. In order for 
bromelain to be widely accepted as a therapeutic agent more trials are 
needed to establish the efficacy and optimall dosage for each clinical 
indication. In addition, since many bromelain preparations contain other 
enzymes and substances, more research is need to identify bromelain’s 
contribution to the  therapeutic effects of these products. 
CONCLUSIONS 
The pineapple compound bromelain has long been used for its 
medicinal properties.,Although the mechanisms of action are just 
beginning to be understood, many studies have suggested that the  
proteolytic component of bromelain is primarily responsible for the 
pharmacological effects. Bromelain may be of interest to plastic surgeons 
because of its apprarent ability to reduce pain, edema, inflammation and 
platelet aggregation, as well as its ability to potentiate antibiotics, which 
may be beneficial in postoperative healing. Bromelain’s reported efficacy 
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in burn debridement and ischemia/reperfusion may also have positive 
applications in plastic surgery. Although bromelain is widely used and 
generally considered to be a safe substance, more randomized, controlled 
clinical trials are necessary to further elucidate its clinical potential. 
Surgical Management of Burn Wounds 
The Procedures used in the surgical management of burns can be 
classified as follows. 
1. Management of partial thickness burns: 
a) Tangential Excision and Split Skin Grafting 
b) Tangential Excision and biological Dressing 
c) Superficial Escharectomy. 
2. Management of full thickness burns 
(a) Escharotomy 
(b) Radical Excision 
(c) Sequential Excision 
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MATERIALS AND METHODS 
PLACE OF STUDY 
 This is a prospective, non-comparative study involving 25 patients 
both mate and female admitted to the burn unit, Department of Burns, 
Plastic and Reconstructive Surgery, Kilpauk Medical College,Chennai. 
PERIOD OF STUDY 
 Jun 2005 – December 2006 
STUDY GROUP 
 25 patients both male and female of age group 15 years to 50years 
with burns of total body surface area of 10-40% were included in the 
study. These patients had burns ranging firm second degree deep to fall 
thickness burns. 
CRITERIA 
1. Patients were excluded in the presence of severe smoke 
inhalation, a recent history of myocardial infarction, 
concurrent acute injury (or) disease that might compromise 
the patient’s life or welfare. Significant hematological, 
cardiovascular, hepatic (or) neoplastic disease or other 
immediate life threatening conditions. 
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2. Patients were also excluded if they had poorly controlled 
diabates mellitus, a history of allergy atopic disease or 
known sensitivity to pineapple (or) were pregnant (or) 
nursing. 
3. Pre and post application investigations like TC, Hemoglobin, 
liver function tests like SGOT, SGPT, SAP, Serum creatinin 
were done to rule out any adverse effect. 
ENZYMATIC AEBRIDEMENT WITH ESCHYLASE 
 Each burn wound was cleaned with saline soaked gauze and 
covered with Heparin soaked gauze for 24hrs. After removing the 
dressing reassessment of the burn’s depth was made. Deep dermal (or) 
full thickness wounds were covered with a mixture of eschalyse gel  
prepared at a concentration of 2g enzyme in 20-40 g hydrating carrier gel 
for every 10 m x 10c m of eschar. 
 The burn wound  were then covered with an occlusive dressing for 
a period of up to 24 hrs. During this period the patient was closely 
observed for the presence of pain or itching and pain relieving 
medication, were given as necessary. 
 Twenty four hours after 1st application occlusive dressing were 
removed aseptically and the entire area wiped clean using a wooden 
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tongue depressor, dry gauze and later with saline soaked gauze until the 
appearance of a clean, bleeding surface (or) until no further eschar be 
removed. 
 After wiping the treated area the wounds were reassessed and 
covered with a saline soaked absorbent dressing for another 24 hours. It 
at this point debridement was deemed still unsatisfactory, Eschalyse gel 
was reapplied. 
Treatment following Eschalyse application 
 Following debridement full thickness burns were graffed with split 
thickness graft. 
 Deep burns with dermal remnants or superficial burns were treated 
conservatively with topical antimicrobial  agents (or) Heparin saline 
dressing and  sometimes with thin split skin graft. 
Outcomes: 
 The primary and points of this study 
1. Extent of achieved debridement 
2. Number of Eschalyse applications  required 
3. Presence of adverse events such as pain, itching, fever, local 
and systemic infection. 
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a. Visuall assessment of debridement efficacy was assessed by 
our Head of the Department and by another chief and 
estimating the amount of original eschar that was removed 
according to the following classification. 
Excellent - 85 – 100% 
Good  - 70 – 85% 
Fair  - 60 – 69% 
Poor  - 50 – 59% 
Failure  - < 49% 
 In case where additional eschalyse was applied the debridement 
efficacy was assessed using the amount of eschar that was removed in 
each application. 
 All the adverse events were recorded during hospitalisation and 
based on past experience with other enzymatic debriding agents fever and 
pain was especially important. 
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RESULTS 
INCIDENCE OF AGE AND SEX IN THE BURNS CASES 
Age group in year Male Female Total 
10 – 20 3 - 3 
21 – 30 4 7 11 
31 – 40 6 2 8 
41 – 50 2 1 3 
Total 15 10 25 
 
 Our study  include mainly patients between ages 20 – 40 years. 
Children were excluded because of ethical reasons. There was a slight 
preponderance towards male 15 Males(60%) , 10 Females(40%). 
CAUSES OF BURNS 
 Male Female Total 
Flame 9 7 16 
Scolds 4 3 7 
Contact 1 1 2 
Total 14 11 25 
 
 Most of our enzyme application was done in flame burns 
16cases(64%) and Scalds 7cases (28%) and we have not applied in 
electrical burn involving the limbs and the flash burns was included in 
flame burns itself and here the contact burns 2 cases (8%) implies to acid 
burns. 
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TOTAL BURN SURFACE AREA 
 Most burns 64% covered < 10% of total burn surface area. Burns 
covering 10 – 40% total burn surface area accounted for 32% of cases 
and burns covering >40% total burn surface area accounted for 4% of 
cases. 
% of Surface Male Female Total 
< 10% 9 7 16 
11 – 40% 4 4 8 
> 40% 1 0 1 
Total 14 11 25 
 
TYPE OF BURNS 
 15 cases (60%) of them were of mixed type 
 8 cases (32%) of them were Deep 
 2 cases (8%) of them were full thickness 
 
 Mixed 2’ Deep Full thick 
Male 10 3 2 
Female 5 5  
 15 8 2 
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DISTRIBUTION OF BURNS  
Upper limb  - 14 case (56%) 
Trunk   - 5 case (20%) 
Lower limb  - 4 case (16%) 
Neck   - 2 case (8%) 
 Upperlimb Trunk Lower limb Neck 
Male 7 4 2 - 
Female 7 2 2 2 
Total 14 6 4 2 
 
NO. OF APPLICATIONS 
Single Application  - 7 cases 28% 
Two Applications  - 12 cases 48% 
Three Applications - 6 cases 24% 
 
 Single 
application 
Double 
application 
Three 
application 
No. of cases 7 cases 28% 12 cases 48% 6 cases 24% 
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PERCENTAGE OF DEBRIDEMENT 
After 1st Application - 70 - 80% 
After 2nd Applications - 80 - 90% 
Type of burns 
1st 
application 
2nd 
application 
3rd 
application 
Mixed 70 – 80% 80 – 90% - 
2nd Degree deep 70 – 80% 80 – 90% 95% 
Full thickness 70 – 80% 80 – 90% 95% 
 
MOST COMMON ADVERSE EVENTS 
That were noted are 
 Fever 
 Localised Pain 
 Burning sensation 
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DISCUSSION 
 The concept of debridement is as old as medicine itself. The first 
reference to debridement appears in the old testatment. The prophet 
Isaiah is quoted. Take a bunch of figs they took and placed the figs on the 
ulcer the Hezekiah recovered. Christopher  Columbus also described the 
use of pineapple juice to promote healing.106 Although the importance of 
the debridement is well-accepted, there is no clear definition of how 
much healthy tissue should be sacrificed in order to achieve adequate 
debridement. The ideal debridement  method should consists of topical 
agent that results in rapid, safe, and effective debridement of necrotic 
tissue with little or any damage to healthy tissue. 
 Chemicals with debriding activity such as acetic acid107 pyruvic 
acid108,109 phosphoric acid110,111 salicylic acid, benzoic acid, mallic acid 
(ascerbine)112,113 trypsin114,116 and fibrinolysin – desoxyribonuclease117,118 
were or still are in current clinical use ever since the second world war. 
These compounds require one or two daily dressing changes for 5-10 
days. As a result, by the time the eschar is removed, a rich granulation 
tissue has already developed with the prospect of future scarring and 
contracture formation. 
 Several enzymes of microbial, vegetable or even animal origin 
have been tested with some even reaching the market. These enzymes 
include those derived from microorganisms such as Clostridium 
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histoliticum H-4: Collagenase (Santyl C)120,124, Bascillus subtilis : 
(Subtilains (C), Streptococci: Streptokinase – streptodornase 
(Varidase)125,126 as well as from plants such as the papaya (papain – urea: 
Accuzyme C)127 or bromelain from the pineapple.14,16,18,127,135 Even 
enzymes made from krill, blowfly larvae extracts, or pancreatic extracts 
have been tried 106,136. 
 Presently only the collagenase: Varidase – Santyl (C), Papain urea: 
Accuzyme and Salicyclic acid are used, relatively rarely in the field of 
burns and acute trauma. Unfortunately these slow acting agents require 
several daily dressing changes for no less than five and sometimes more 
than 12 days to be effective or end up with an incomplete debridement 
that necessitates additional surgical debridement. The repeated 
application of these agents has been followed in several cases by local 
and systemic infection due to bacteremia secondary to the repeated 
handling and occlusion of the contaminated eschar with exposure of the 
surrounding raw tissues to the contaminated the partially dissolved 
eschar.10,13 
 The aim of the current study was to evaluate the efficacy of burn 
wound debridement using the Eschalyse enzymatic preparation as well as 
to evaluate the presence of any possibly related adverse events. Direct 
assessment of the debridement thoroughness (efficacy) and its safety was 
sought as the primary end points and not graft take as many factors 
besides the host bed influence the graft take as many factors besides the 
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host bed influence the graft take. Another reason for not including graft 
take as a measure of debridement efficacy is the fact that selective 
enzymatic debridement removes only the necrotitc tissues and deep but 
not full thickness burns may still heal by epithelialization of the surving 
dermal bed from the epidermal adnexae without the need for 
transplantation surgery. This differs significantly from surgical 
debridement where in most cases the full thickness of the skin in 
sacrificed for the sake of debridement and transplanation of a skin graft is 
mandatory. 
 The study population is fairly typical of our burn unit population, 
though slightly more representative of adults since judicious inclusion of 
children in the study was encouraged. The mean BSA of the deep burns 
that required debridement and were treated by was less than 7% of BSA. 
The majority of burns were debrided using two applications of Eschalyse. 
In the remainder of cases for which two or more applications were 
required the wound was usually old, dry or saturated with silver 
sulfadiazine (SSD). A pressure contact burn of the fingers and the other 
of Old SSD treated scaled burn of the arm, three consecutive applications 
were required. 
 In most cases the debridement was completed in less than 5 day. In 
average, the first application removed nearly 75% of the entire eschar, the 
second (if needed) 85% and in the few cases  in which a third application 
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was used, 95 of the eschar was eventually removed. In nearly three 
quarters of the cases two 24 hour application was sufficient with a gap of 
24 –36 hours to complete this phase of the treatment. 
 In one case of Acid burns involving thigh grading to full thickness 
even after three applications we were not able to remove the eschar 
except it become loose and we dont get a good result or failure in acid 
burns and the exact reason not known. 
 During the early phases of the study many of the debrided wound 
beds that had typical features of a non surgical debrided bed were 
misinterpreted only as partially debrided, skewing  the results against. 
Once it became clear that this bed was clean and could heal 
spontaneously or support a skin graft the results “improved”. In some 
difficult areas (such as on the trunk or on  convex areas where the 
debriding gel could not be in close and continuous contact with the 
eschar) additional applications were required to complete the debridement 
of the entire intended area. Early on the importance of removing all the 
superficial burned keratin layer (blisters) that hinder the action of the 
enzymes was realized. Dry and old eschars, especially if treated with SSD 
for several days, did not dissolved as well as fresh most ones.  Thus the 
efficacy of Debridase decreased after the 6th post burn day possibly due to 
the changing nature of the eschar following treatments such as SSD. 
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 Five patients with extensive buras were treated  several times, each 
time for no more than 15% TBSA of the burned area. In such cases 
eschalyse dressings were applied sequentially after removing the 
previously debrided dressings. 
 Approximately one quarter of the burns were completely debrided 
within the first day with another half undergoing complete debridement 
within 2-3 days of injury. These results are even more impressive when 
one considers that in some cases (e.g., more extensive burns) sequential 
applications of eschalyse were used. In all cases where enzymatic 
debridement with eschalyse was complete, skin allografting, for 
biological, epithelialization  enhancing cover or other topical covers were 
performed  at the bedside with minimal pain and no bleeding. In cases of 
full thickness burns and an excellent eschalyse debridement the grafting 
of an autograft could be done without a farther surgical debridement and 
without the repeated blood transfusions in case of repeated surgery and 
furthur grafting the recipient bed prepared by scraping or 
dermabrasion.Total duration of stay in the hospital were drastically 
reducedand seems to be very cost effective. Psychological and 
rehabilitative part on behalf of the patient remains easy. This is obviously 
of great benefit when compared to the pain and bleeding associated with 
surgical debridement, The  selectivity of the preparation was 
demonstrated by the lack of effect on the healthy  surrounding tissue and 
the preservation of remnants of unburned tissues (dermis and epidermis). 
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Finally, unlike other non surgical debridement techniques, eschalyse 
achieved  a thorough debridement in a single or double  application 
offering a rapid  and selective burn wound debridement method. 
 Many patients complained of various sensations at the treated area 
immediately on application on eschalyse. These sensations ranged from a 
vary mild tingling or discomfort to a mild  burning or itching with some  
requiring oral analgesia mainly with the more superficial burns. Most of 
these complaints subsided within 30 min  of eschalyse application, but 
some patients complained of an itching or burning sensation for the entire 
duration of the treatment. Typically, the more intense sensations started to 
decrease after 15-20 min of treatment reaching a level very mild irritation 
within 30 min of application. Prophylactic pre-treatment of patients with 
analgesic agents (as is customary before dressing changes) usually was 
sufficient to keep the patients comfortable. None of our patients required 
sedation or general anesthesia for the treatment. 
 Fever was noted in nearly 80% of our patients, however fever is 
common after thermal injuries and the exact relationship to the 
debridement is unclear. It should be noted that 2/3 of our patient 
population  did not develop any fever beyond the first 2 days after injury 
when in general fever becomes more common. Also we did not find that 
the temperatures of patients treated with eschalyse were any higher than 
in our other burn patients during the study period that were not treated 
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with enzymatic debridement. Only a Large prospective randomized 
comparative trial will help determine the relationship between enzymatic 
debridement with and the occurrence of fever. 
Our study has several limitations that merit further discussion. 
Further –more this was not a comparative trial, thus it is unclear what the 
exact impact of enzymatic debridement compared to the standard of care 
tangential excision was.  
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SUMMARY AND CONCLUSIONS 
 25 patients with 10-40% burn admitted to tertiary care center were 
included in the study. 
 Majority of the patients affected were 20-30 years of age. 
 Children were not included in the study. 
 There was a slight male preponderance  15 cases(60%) in our study 
population. 
 Commonest cause of burns included in the study were flame 
burns16cases(64%), followed by scalds(28%), and contact burns 
2cases(8%).  
 Patients with <10% of total burn surface area formed 64% of the 
study population. 
 Patients with  myocardial infarction, concurrent acute injury, 
significant haematological, cardiovascular, hepatic diseases were 
excluded. 
 Bromelain is a well known group of enzymes extracted from 
pineapple fruits (or) stems. It contains more than 50 different 
components and is widely used  as an over the counter food 
additive and is also used in the cosmetic industry. 
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 Most burns included in our study were of mixed burns 15 cases 
(60%),  while 8 cases( 32%)  were of deep dermal burns. 
 Majority of the burns  included in our study involves upper limb 
14cases (56%), Trunk 5 cases (20%), Lowerlimb 4 cases (16%) & 
Neck 2cases(8%). 
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CONCLUSIONS 
 On analyzing our result we achieved  debridement with single 
application in 28%  of cases, and two applications in 48%  of cases 
and three applications in 24% of  cases. 
 Percentage of debridement achieved with single application  is 70± 
10% and after two applications we achieved 80±10% and  after 3 
applications we achieved around 95 ± 5%. 
 Approximately one quarter of the burns were completely debrided 
with in one or two days and another half complete debridement 
with in 3-4 days and in some extensive burns sequential application 
helps us to achieve the debridemnet in a short time. 
 . In all cases where enzymatic debridement with eschalyse was 
complete, skin allografting, for biological, epithelialization  
enhancing cover or other topical covers were performed  at the 
bedside with minimal pain and no bleeding. 
 . In cases of full thickness burns and an excellent eschalyse 
debridement the grafting of an autograft could be done without  
further surgical debridement and without the repeated blood 
transfusions in case of repeated surgery and furthur grafting the 
recipient bed prepared by scraping or dermabrasion. This is 
obviously of great benefit when compared to the pain and bleeding 
associated with surgical debridement and the patient not subjected 
to repeated anesthesia. 
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 The  selectivity of the preparation was demonstrated by the lack of 
effect on the healthy  surrounding tissue and the preservation of 
remnants of unburned tissues (dermis and epidermis). Finally, 
unlike other non surgical debridement techniques, eschalyse 
achieved  a thorough debridement in a single or double  application 
offering a rapid  and selective burn wound debridement method 
 Total duration of stay in the hospital were drastically reduced and 
seems to be very cost effective. 
 Psychological and rehabilitative part on behalf of the patient 
remains easy. 
 Fever, localized pain and burning sensation were observed as side 
effects and managed appropriately. No specific morbidity and 
mortality noted. 
  To conclude the availability of a rapid, reliable and complication 
free enzymatic debriding agent may open new horizons and 
provide a new treatment modality for burn wound management. 
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APPENDIX 
Eschalyse gel  
 Mixture of  eschalyse powder and carrier hydrating gel at a 
Concentration of  2g enzyme in 20-40g hydrating carrier gel  for every 
10cm x 10 cm of eschar. 
Heparin Saline Dressing 
 1 vail containing 5000 IU in 100ml of normal Saline used for 
covering 10% of burn surface area. 
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PROFORMA 
Name  :    D.O.A : 
Age  :    D.O.D: 
Sex  :    IP NO : 
Occupation :    Ward No: 
Education :    Weight : 
Marital Status:    Time of incident : 
Time of Starting treatment: 
Type of Burns:  Flame Scalds     Contact       
Degree of the burns: 
Depth of the burns : Superficial  Deep 
Sites Affected : 
Sites Affected 
Head 
Neck 
Anterior trunk 
Posterior trunk 
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Right buttock 
Left buttock 
Genitalia 
Right upper arm 
Left upper arm 
Right hand 
Left hand 
Left thigh 
Right leg 
Left leg 
Right foot 
Left foot 
No. of Applications 
%  of debridement achieve after 
 Ist Application 
2nd Application 
3rd Application 
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ABBREVIATION 
SGOT : SERUM ALANINE AMINOTRANSFERASE 
SGPT : SERUMASPARTATEAMINO 
TRANSFERASE 
 SAP  : SERUM ALKALINE PHOSPHATASE 
TC  : TOTAL COUNT 
 TBSA : TOTAL BURN SURFACE AREA 
 SSD  : SILVER SULFADIAZINE 
PMN : POLYMORPHONUCLEAR LEUCOCYTES 
 PG  : PROSTAGLANDINS 
 SOD  : SUPEROXIDE DISMUTASE 
 NK  : NATURAL KILLER CELLS 
 NADPH : NICOTINAMIDE ADENINE DINUCEOTIDE 
PHOSPHATE DEHYDOGENASE
 53
BIBLIOGRAPHY 
1. Sheridan RL, Tomppppkins RG, Burke JF, Management of burn 
wounds with prompt excision and immediate closure [see 
comments] J. Intensive Care, Med 1994:9:6 –17. 
2. Sheridhan R.Remensnyder J.Prelack K.Petras L.Lydon 
M.Treatment of the seriously burned infant. J.Burn Care Rehabil 
1998:19:115-8. 
3. Prasanna M.Singh K.Kumar P.Early tangential excision and skin 
grafting as a routine method of burn wound management, an 
experience from a developing country. Burns 1994:20:446-50. 
4. Monafo WW.Tangential excision, Clin Plast Surg 1974:1:591-601 
5. Nada, Y.Sasaki K.Nozaki M. Takeuchi M. Chen. X. Nakazawa H. 
The effect of early burn wound excision on regional gastric blood 
flow in rats. Burns 1998:24:519-24. 
6. Janzekovie Z A New concept in the early excision  and immediate 
grafting of burns. J.Trauma 1970 :10: 1103-8. 
7. Salisbury RE. In. Thermal burns. Mc Carthy JG. Editor, Plastic 
surgery, vol. 1 Philadelphia PA :WB Saunders Company : 1990 p. 
787-830. 
 54
8. Miller JG.Carruthers HR. Burd DA. An algorithmic approach to 
the management of cutaneous burns. Burns 1992:18:200-11 
9. Klasen HJ. A review on the non operative removal of necrotic 
tissue from burn wounds, Burns 2000:26:207-22. 
10. Hummel RP. Kautz PD, Mac Millan BG. Altemeier WA. The 
continuing  problem of sepsis –following enzymatic debridement 
of burns.J Trauma 1974:14:572-9. 
11. Silverstein P.Maxwell PLD. Enzymatic debridgement. In : 
Boswick JA editor. The art and science of burn care. Rockville: As 
per Publishers; 1987.p.75-81. 
12. Connell, JF. Rousselot LM. The use of proteolytic enzymes in the 
debridement of the burn eschar. Surg Forum 1953 Philadephia  
1954:422-7. 
13. Krizek TJ.Robson MC Groskin MG. Experimental burn wound 
sepsis – evaluation of enzymatic debridement J.Surg Res 
1974:17:219-27. 
14. Klein GK V Historical development of bromelain in the treatment 
of burn wounds. In May D.Editor. Care of the Burn Wound. 
International Congress, Geneva, 1983 Basel : Karger 1985, p.90-6. 
 55
15. Klein GVK. Enzymatic debridement of third degree burns in 
animals with bromelains – a preliminary report. J. Maine Med 
Assoc. 1964:55:169-71. 
16. Levenson S.Supportive therapy in burn care. Debriding agents.J 
Trauma 1979:19:928-30. 
17. Levine N.Seifter E.Connerton C.Levenson SM. Debridement of 
experimental skin burns of pigs with bromelain, a pineapple stein 
enzyme, Plast Reconstr Surg 1973:52:413–24. 
18. Rowan, AD, Christopher CW, Kelley SF, Buttle DJ, Ehrlich HP, 
Debridement of experimental full-thickness skin burns of rats with 
enzyme fractions derived from pineapple stem. Burns 1990:16: 
243 –6. 
19. Houck JC, Chang CM, Klein G. Isolation of an effective debriding 
agent from the stems of pineapple plants. In J Tissue React 1983; 
5: 125-134. 
20. Monafo WW. Freedman B. Topical therapy for burns, surg clin 
north Am 1987: 67: 133-45. 
21. Hansbrough JF. Burn wound sepsis. J Intensive care med 1987: 2: 
313-27. 
 56
22. Manson WL. Pemot PCJ, Fidler V. Sauer EW. Klasen JH 
Colonisation of burns and duration of burns of severely burned 
patients J Hosp infect 1992: 22: 55-63. 
23. Grobmyer SR, Maniscalco SP, Purdue GF, et al: Alcohol, drug 
intoxication, or both at the time of burn injury as a predictor of 
complications and mortality in hospitalized patients with burns. J 
Burn Care Rehabil 1996, 17: 532. 
24. Barillo DJ, Brigham PA, Kayden DA, et al: The fire-safe cigarette: 
A burn prevention tool J Burn care Rehabil 2000, 21: 162, 
discussion 16. 
25. Saffle JR, Davis B . Williams P: Recent outcomes in the treatment 
of burn injury in the United States: A report from the American 
Brun Association Patient Registry. J Burn Care Rehabil 16: 219, 
1995: discussion 288. 
26. Pruitt BA Jr.: Centennial changes in surgical and research Ann 
Surg 2000, 232: 287. 
27. Herndon DN, Spies M: Modern burn care. Semin Pediatr Surg 
2001, 10: 28. 
28. Munster AM: Burns of the world. J Burn Care Rehabil 1996, 17: 
477. 
 57
29. Islam SS, Nambiar AM, Doyle EJ, et al: Epidemiology of work 
related burn injuries. Experience of a state – managed workers 
compensation system. J Trauma 2000, 49: 1045. 
30. Simeone FA: Shock, in Davis L (ed): Christopher’s Textbook of 
surgery, Philadelphia, W.B. Saunders Co., 1964, 58-62. 
31. Demling RH: Fluid Resuscitation, in Boswick JA (ed): The art and 
science of burn care. Rockville, Aspen Publishers, 1987; 189-202. 
32. Order SE, Mason AD, Switzer WE, et al. Arterial vascular 
occlusion and devitalisation of burn wounds. Ann. Surg. 1965; 
161; 502-508. 
33. Massiha H, Monafo WW: Dermal ischemia in thermal injury. The 
importance of venous occlusion. J. Trauma 1974: 14: 705-711. 
34. Noble HGS, Robson, MC, Krizek TJ: Dermal ischaemia in the 
burn wound. J. Surg Res. 1977: 23: 117-125. 
35. Contran RS: The delayed and prolonger vascular leakage in 
inflammation. II. An electron microscope study of the vascular 
response after thermal injury. Am. J. Patho 1965; 46: 589-620. 
36. Nozaki M, Guest MM, Bon TP, et al. Permeability of blood vessels 
after thermal injury. Burns 1980; 6: 213-221. 
 58
37. Cope O, Moore FD: A study of capillary permeability in 
experimental burns and burn shock using radioactive dye in blood 
are lymph. J. Clin. Invest. 1944; 23: 241-257. 
38. Mason AD, Pruitt BA, Moncrief JA: Hemerdynamic changes in the 
early post period: The influence of fluid administration and a 
vasodilator. J. Trauma 1971: 11: 36-46. 
39. Davies JWL: Capillary permeability, oedema and lymph, in 
physiological responses to burning injury. New York, Academic 
press Inc, 1982: 45-105. 
40. Arturson G, Wallenius G: Hypercoagulability of blood  after burn 
trauma in rats. A preliminary report. Acta. Chri. Scand, 1964; 128: 
340-345. 
41. Baxter CR: Fluid volume and electrolyte changes of the early 
postbunr period. Clin. Plast. Surg. 1974; 1: 693-709. 
42. Demling RH, Mazess RB, et al., The study of burn wound edema 
using dichromatic asborptionmetry. J. Truma 1978; 18: 124-127. 
43. Glenn WWL, Peterson DK, Drinker CK: The flow of lymph from 
burned tissue with particular reference to the effect of fibrin 
formation on lymph drainage and composition. Surgery 1942; 12: 
685-693. 
 59
44. Aikawa N, Ishibiki K, Naito C, et al. Individualized fluid 
resuscitation based on haemodynamic monitoring in the 
management of extensive burns. Burns, 1982; 8: 249-255. 
45. Brounhard B, Carvajal H, and Linares H: Burn edema and protein 
leakage in the rat. Microvasc. Res. 1978; 15: 221-228. 
46. Wilson JS, Moncrief JA: Vapor pressure of normal and burned 
skin. Ann. Surg. 1965; 162: 130. 
47. Lamke L: Evaporative water loss from normal and burnt skin. 
Scand. J. Plast. Reconstr. Surg. 1971; 5: 17. 
48. Munster AM: The early management of thermal burns. Surgery 
1980; 87: 29-40. 
49. Reaves LE, Antonacci AC, Shires GT:  Fluid and electrolyte 
resuscitation of the thermally injured patient. World J. Surg. 1983; 
7; 566-572. 
50. Moncrief J: The body’s response to heat, in Artz C,  Moncrief J, 
Pruitt B (eds): Burns: A team approach. Philadelphia, W.B. 
Saunders, 1979; 23-44. 
51. Jelenko C, Jennings WD, O’Kelley WR, et al: Threshold burning 
effects on distant microcriculation. III. Presence of a passively 
transferable, non-dialyzable arteriolar constriction substance in 
blood of burned patients. Amer. Surg. 1974; 40: 388-391. 
 60
52. Jelenko C, O’kelley WR, Byrd HC, et al., Threshold burning 
effects on distant microcirculation. IV. Development of an in vitro 
method for demonstrating  vasoactivity in postburn plasma. J. 
Surg. Res. 1976; 20: 7-10. 
53. Eriksson E, Plmy – Foreshell K, Robson MC: Distant 
microcirculatory changes after a major burn: effects of methyl 
prednisolone, dextran 40, heparin and normal saline. Burns 1981; 
7: 158-161. 
54. Eriksson E, Robson MC: New pathophysiological mechanism 
explaining post burn edema. Burns 1978; 4: 153-156. 
55. Arturson G: Pathophysiological aspects of the burn syndrome. Acta 
Chir. Scand.  (suppl). 1961; 274: 55-108. 
56. Branemark PL, Breine J, Josehi M, et al. Microvascular 
pathophysiology of burned tissue. Ann. N.Y. Acad. Sci. 1968: 150: 
474. 
57. Cotran Rs, Remensnyder RP: The structural basis of increased 
vascular permeability  after graded thermal injury. Light and 
electron microscope studies. Ann. N.Y. Acad. Sci. 1968; 150: 474. 
58. Demling RH, Kramer GC, Gunther R, et al. Effect of nonprotein 
colloid on postburn edema formation in soft tissues and lung. 
Surgery 1984; 95: 593-602. 
 61
59. Harms BA, Bodai B, et al. Microvascular fluid and protein fluid in 
pulmonary and systemic circulations after thermal injury. 
Microvasc. Res. 1982; 23: 77-86. 
60. Tranbaugh RF, Lewis FR, Christensen JM, et al. Lung water 
changes after thermal injury. The effects of crystalloid resuscitation 
and sepsis, Ann. Surg. 1980; 192: 479-490. 
61. Davies JWL. Changes in the colloid osmotic pressure of serum 
from patients with burns or other injuries, in Birke G, Norberg R, 
Plantin LO (eds); Physiology and pathophysiology of plasma 
protein metabolism. Pergamon press, Oxford 1969; 249-259. 
62. Demling RH, Kramer GC, Harms B: Role of thermal injury 
induced hypoproteinemia on edema formation in burned and non-
burned tissue. Surgery 1984; 95: 136-144. 
63. Kramer GC, Harms BA, Gunther R, et al. The effects of 
hypoproteinemia on blood to lymph fluid transport on sheep lung. 
Circ. Res. 1981: 49: 1173-1180. 
64. Kramer G, Gunther R, Nerlich M, et al: Effect of dextran 70 on 
increased microvascular fluid and protein flux after thermal injury. 
Circ. Shock 1982; 9: 529-541. 
65. Kramer GC, Harms BA, Bodai B, et al. Mechanisms for 
redistribution of plasma protein following acute protein depletion. 
Am. J. Physiol. 1982; 243: 803-809. 
 62
66. Baxter CR: Guidelines for fluid resuscitation. J. Trauma 1981; 21: 
667-668. 
67. Demling RH: Fluid resuscitation after major burns. J.A.M.A., 
1983; 250: 1438-1440. 
68. Moyer CA, Margraft W, Monafo WW: Burn shock in association 
with extravascular sodium deficiency. A report on the treatment 
with Rnger’s solution with: lactate. Arch. Surg. 1965; 90-799. 
69. Arturson G: Microvascular permeability macromolecules in 
thermal injury. An physiol. Scand. (Suppl) 1979; 463: 111-222. 
70. Leape L: Tissue changes in burned a unburned skin of rhesus 
monkeys.J. Trau 1970; 10: 488-492. 
71. Hiinshaw JR: Progressive changes in de of burns. Arch. Surg. 
1963; 87: 131. 
72. Cuppage FC, Leape LL, Tate A: Morphological changes in rhesus 
monkey skin a acute burn. Arch. Path. 1973; 95; 402-404. 
73. Baxter CR, Shires T: Physiological respond to crystalloid 
resuscitation of severe bur Ann. N.Y. Acad. Sci. 1968; 150: 874-
893. 
74. Shires GT, Carrico CJ, Baxter CR, et al. Early resuscitation of 
patients with burn welch, CE (ed): Advances in surgery  4: 255-
324. 
 63
75. Goodwin CW, Dorethy J, Lam V, et al. Randomized trial of 
effectve of erystal and colloid resuscitation on hemodynresponse 
and lung water following the injury. Ann. Surg. 1983; 197: 520-
531. 
76. Topley E, et al: Assessment of reduce in the first two days after 
severe burns. Surg. 1962; 155: 581. 
77. Wilmore D: Metabolic changes in burn Artz C, Moncrief J, Pruitt 
B (eds): But team approach Philadelphia, WB ders, 1979, 120-131. 
78. Baxter RC: Problems and complication burn shock resuscitation 
surg. Clin. Am. 1978; 58: 1313-1322. 
79. Lotz-Winter, H.On the pharmacology of bromelain: An update 
with special regard to animals studies on dose-dependent effects. 
Planta Med.56:249, 1990. 
80. Heinicke, R.M., and  Gortner, W.A., Stem bromclain: A new 
protease preparation from pineapple plants. Ecom. Bol.11:225, 
1957. 
81. Tanssig, S.J. Yokoyama, M.M., Chinen, A., et al. Bromelain: A 
proteolytic enzyme and its clinical  application. Himshima 
J.Med.Sci 24: 185, 1975. 
 
 64
82. Maurer, H.R. Brokelian: Biochemistry, Pharmacology and medical 
use. Cell Mol. Life Sci.58: 1234, 2001. 
83. Rowan, A.D and Buttle, D.J.Pineapple cysteine endopeptidases. 
Methods Enzymol. 244:555, 1994. 
84. U.S. Food and Drug Administration, Partial  list of enzyme 
preparatiosn that are used in foods. Washington, D.C. U.S. Food 
and Drug Administration, Centr of Food Safety and applied 
Nutrition Office of Food Additive Safety, Available at 
http:/www.cfsan.fda gov-dms opa html.Accessed May 24, 2006. 
85. Hale, R.H. Rasheedi, S. and Haq. S.K. Effect of pH, temperature 
and alcohols on the stability of glycosylagted and deglycosylated 
stem bromelain. J. Biosci 28, 709, 2003. 
86. Khan, R.H. Rasheedi, S., and Haq, S.K.Effect of pH, temperature  
and alcohols on the stability of glycosylated and deglycosylated 
stem bromelain. J.Biosci. 28:709, 2003. 
87. National Library of Medicine and National Institute of Health . 
Bromelain. Available at Medline plus, bromeclain. Html. Accessed 
May 24, 2006. 
88. Zatuchni, G.I and Colombi, D.J. Bromelains therapy for the 
prevention of episiotomy pain. Obstel Oynercol 29:275, 1967. 
 65
89. Bodi, T. The Effects of oral bromelains on tissue permeability to 
antibiotics and pain response to bradykinin: Double blind studies 
on  human subjects. Clin Med. 73:61, 1966. 
90. Walker, A.F., Bundy, R.Hicks, S.M. et al. Bromelain reduces mild 
acute knee pain and improves well-being in a dose dependent 
fashion in an open study of otherwise healthy adults. 
Phytomedicine 9:681, 2002. 
91. Stone, M.B. Merrick, M.A. Ingersoll, C.D. et al. Preliminary 
comparison of bromelain and ibuprofein for delayed onset muscle 
soreness management. Clin. J. Sport Me. 12 373, 2002. 
92. Setlzer, A.P.A. double-blind study of bromelains in the treatment 
of edema and echymoses following surgical and non-surgical 
traumat to the face. Eye Ear Nose throat Mon-43: 54, 1964. 
93. Neumayer, C. , Fugl., A., Nanobashvili, J., et al, Combined 
enzymatic and antioxidative treatment reduced. 
94. Gaspani, I., Limiroli, E., Ferraio, P., and Bianchi, M. In vivo and in 
vitro effects of bromelain on PGE and SP concentrations in the 
inflammatory exudates in rats. Pharmacology 65: 83, 2002. 
95. Hale, L.P., Greer, P.K. Trinh, C.T. et al. Treatment with oral 
brometlain decreases colonic inflammation in the IL-10 deficient 
murine model of inflammatory bowel disease. Clin. Immunol  
116:135, 2005. 
 66
96. Secor, E.R. Carson, W.F. IV, Cloutier M.M. et al. Bromelain exerts 
anti-inflammatory effects in an ovalbumin-induced murine model 
of allergic airway disease. Cell. Immunol. 237: 68, 2005. 
97. Kane, S., and Goldberg M.J. Use of bromelain for mild ulcerative 
colitis. Ann. Intern. Med. 132:680, 2000. 
98. Howat, R.c.L., and Lewis, G.D. The effect of bromelain therapy on 
episiotomy wounds. A double blind controlled clinical trial J. 
Obstet, Gynaecol. Br.Commono. 79:951, 1972. 
99. Brown. S.A., Coimbra M., Coberly, D.M. et al. Oral nutritional 
supplementation accelerates skin wound healing : A randomized, 
placebo-controlled, double –arim crossover study. Plast. Recont, 
Surg 114: 237, 2004. 
100. Heiniche, R.M. Vander Wal, L., and Yokoyama, M.M. Effect of 
bromelain (Annanase) on human platelet aggregation. Experientia 
28: 844, 1972. 
101. Livio, M. Bertoni, M.P., DeGaetano, G., et al. Effect of bromaclain 
on fibrinogen in the rate: A preliminary report, Drug. Exp. Clin. 
Res. 4:49, 1978. 
102. Galaser, D and Hilberg. T. The influence of bromelain on plaelet 
count and platlet activity in vitro. Plately 17:37, 2006. 
 67
103. Tinozzi, S., and Venegoni, A. Effect of bromelain on serum and 
tissue levels of amoxicillin. Drugs Exp. Clin.Res.4:39, 1978 
104. Shahid, S.K. Turakhia, N.H. Kundra, M. et al Efficacy and safety 
of phlogernzym: A protease formulation, in sepsis in children. 
J.Assoc, Physicians India 50:527, 2002. 
105. Levine, N., Sifter, E., connerton, C. et al., Debridement of 
experimental sin burns of pigs with bromelain, a pineapple stem 
enzyme. Plast Recontr surg 52:413, 1973. 
106. Rosenberg, L, Lapid, O., Bogdano-Berezovsky, A., et al Safety and 
efficacy of a proteolytic enzyme for enzymatic burn debridement: 
A preminlary report, Burns 30: 843, 2004. 
107. Krieger, Y., Rosenberg, L. Lapid O et al Eschatotomy with an 
enzymatic debridgement agent for treating experimental burn-
induced compartment syndrome in an animal model. J. Trauma 58: 
1259, 2005. 
108. Brien S. Lewith, G., Walker, A., et al. Bromelain as a treatment for 
osteoarthrists. A review of clinical studies. Evid. Based 
Complement, Alternal, Med 1: 251, 2004. 
109. Galleguillos, F., and Rodriguez. J.C. Asthma caused by bromelin 
inhaltion, Clin Allergy, 8:21, 1978. 
 68
110. Baur, X., and Fruhmann, G. Allergic reactions, including asthma, 
to the pineapple protease bromelain following occupational 
exposure. Clin. Allergy, 9: 443, 1979 
111. Gailhofer, G., Wilders Trusching, M., Smolle, J. et al.  Asthma 
caused by bromelain: An occupational allergy 18: 445, 1988. 
112. Abede, W. An overview of herbal supplement  utilization with 
particular emphasis on possible interactions with dental drugs and 
oral manifestations, J.dent. Hyg. 77:37, 2003. 
113. Vincent J. Traitement Fibrinolitique actuel par des enzymes pour 
les soin des Plais. J des palies et Cicatrisations 1999: 14-7. 
114. Dorance GM, Brandfield JW.Burns, with special reference to 
acetic treatment, Surg Clin North Am 1923, 2: 299-307. 
115. Connor GJ, Harvey SC. The pyruvic acid method in deep clinical 
burns. Ann Surg 1946: 124: 799-810. 
116. Lam, CR, Puppendahl M. The pyruvic acid method of burn slough 
removal. Ann Surg 1945; 121: 866-71. 
117. Schweitzer RJ, Bradsher JT. Acid debridement of burns with 
phosphoric acid gel, N. Engl. J. Med 1951: 244: 705-9. 
118. Mir Y, Mir L, Benedito R. Debridement by acids in the general 
treatment of patients with extensive burns. Transactions of the 
Third International Congress of Plastic Surgery. Amsterdam, 1964. 
Excerpta Medica Foundation. Broadbent TR: 177-82. 
 69
119. Crawford BS, Rozner L. A clinical trial of a desloughing agent in 
burns. A preliminary report, Br. J. Plast Surg 1966: 19: 154-60. 
120. Lloyd DA, Mickel RE, Kritzinger NA. Topical treatment of burns 
using asrbine. Burns 1989; 15: 125-8. 
121. Rodeheaver G, Edgerton MT, Elliott MB, Kurtz LD, Edllich RF. 
Proteolytic enzymes as adjuncts to antibiotic prophylaxis of 
surgical wounds. Am. J. Surg 1974; 127: 564-72. 
122. Rodeheaver G, Marsh D, Edgerton MT, Edlich RF. Protolytic 
enzymes as adjuncts to antimicrobial prophylaxis of contaminated 
wounds. Am J. Surg 1975; 129: 537-44. 
123. Rodeheaver G, Wheeler CB, Rye DG, Vensko J, Edlich RF. Side 
effects of topical proteolytic enzyme treatment. Surg Gynecol 
Obstet 1979; 148: 562-6. 
124. Roman – Calderon J. Treatment of second and third degree burns: 
Comparison of effect of proteolytic enzyme combination and silver 
nitrate. Curr Ther RTes Clin Exp. 1982: 32: 305-11. 
125. Chapple JS. Elase and wand debridement N Z  Med J. 1984: 97: 
701. 
126. Westerhof W, Jansen FC, de Wit FS, Cormane RH. Controlled 
double blind trial of fibrinolysin – desoxyribonuclease (Elase) 
solution in patients with chronic leg ulcers who are treated before 
autologous skin grafting (Ointment). J.Am. Acad Dermatol 1987; 
17: 32-9. 
 70
127. Soroff HS, Sasvary DH. Collagenase and polymyxin B 
sulfate/bacitracin spray versus silver sulfadiazine cream in partial 
thickness burns: a pilot study. J. Burn Care Rehabil 1994: 15: 13-7. 
128. Hansbrough JF, Achauer B. Dawson J., et al. Wound healing in 
partial thickness burn wounds treated with collagenase ointment 
versus silver sulfadiazine cream. J. Burn Care Rehabil 1995; 16: 
241-7. 
129. Radice M, Brun P, Bernardi D, Fontana C, Cortivo R, Abatangelo 
G. Clostridial collagenase releases bioactive fragments from 
extracellular matrix molecules. J. Burn Care Rehabil 1999; 20:  
28-91. 
130. Ozcan C, Ergun O, Celik A, Corduk N, Ozok G, Enzymatic 
debridement of burn wound with collagenase in children with 
partial thickness burns. Burns 2002; 28: 791-4. 
131. Hamit HF, Upjohn HL. Debridement of experimental burn with 
clostridium histolyticum H-4 enzymes. Ann Surg 1960: 151-589-
93. 
132. Teitelman SL, Movitz D, Zimmermen LM, Enzymatic debridement 
of necrotic surfaces. Ann Surg 1952: 136: 267-71. 
133. Blomgren, I, Eriksson E, Lauritzen  C, A clinical study of Trypue 
of varidase on minor burns. Scand J. Plast Reconstr Surg 1985: 19: 
101-3. 
 71
134. Burke JF, Golden TD. A clinical evaluation of enzymatic 
debridement with papain – urea – chlorophyllin ointment. Am J. 
Surg 1958: 95: 828-42. 
135. Guzman A, Guzman MG. The enzymatic debridement of 
suppurations, necrotic lesions and burns with papain. J Int Coll 
Surg 1953: 20; 695-702. 
136. Starley IF, Mohammed P, Schneider G. Bickler SW. The treatment 
of paediatric burns using topical papaya. Burns with papain. Burns 
1999: 25: 639-9. 
137. Levine N, Seifter E, Levenson SM. Enzymatic debridement of 
burns. Surg Forum 1971: 22:57-8. 
138. Levenson SM, Gruber DK, Gruber C, Lent R, Seifter E, Chemical 
debridement of burns: mercaptans, J. Trauma 1981: 21: 632-44. 
139. Levenson SM, Kan D, Gruber C, et al. Chemical debridement of 
bruns, Ann Surg 1974; 180: 670-704. 
140. Kan D, Gruber C, Watford A, Seifter E, Levenson SM. Chemical 
debridement of burns with N-acetylcysteine. Surg Forum 1979; 30: 
48-50. 
141. Boswick JA. Clinical Experience with a new enzymatic debriding 
agent, Basel: Karger: 1985. 
 72
142. Eldad. A, Weinberg A, Breiterman S. Chaouat M, Palanker D. Ben 
Bassat H. Early nonsurgical removal of chemically injured tissue 
enhances wound healing in partial thickness burns. Burns 1998: 24: 
166-72. 
143. Vistnes I, M., Lee R. Ksander GA. Proteolytic activity of blowfly 
larvae secretions in experimental burns. Surgery 1981: 90; 835-41. 
